List of Gene Therapy Companies in Virginia - 12

Celetrix is the leader in electroporation with our new high efficiency electroporation technologies for delivering DNA, RNA and proteins to cells. Celetrix provides technology and support for CAR-T manufacturing by transposon mediated expression and RNP mediated gene editing for T cells, stem cells and CD34+ HSC.

DYNEX Technologies Inc. is a pioneer in the design and manufacturing of fully automated ELISA and Chemiluminescence microplate technology. Our fully automated line of ELISA testing instruments and consumables continue to raise the bar in laboratory optimization and efficiency. With over 8,500 instruments worldwide, DYNEX® offers solutions with increasing levels of throughput to support laboratories of all sizes and specialties. Be assured that the DYNEX family of U.S. manufactured, ISO certified instruments, will remain a steady and reliable component to achieving optimal laboratory proficiency.

Experimental Pathology Laboratories, Inc. (EPL®) is recognized internationally for its ability to meet the needs of the scientific community and the challenges of preclinical safety testing with high quality, on-time histopathology services. EPL’s wholly owned subsidiary, Aclairo, has seamlessly integrated their efforts with our core histopathology services to provide expert toxicological, pharmacological, DMPK and clinical pharmacology support. Together, we are Experienced Proven Leaders.

LumaCyte’s advanced real-time bioanalytics platform, Radiance®, is a label-free, single cell approach for quantitative characterization of innate cellular responses, without the need for antibody or genetic labeling. This revolutionary technology utilizes Laser Force Cytology™ (LFC) to measure subtle phenotypic changes based purely on the intrinsic biophysical and biochemical properties of cells in response to their environment and/or treatment.

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com. Mission: Managing Complexity. Improving Lives. Values: Quality, Integrity, Service Principal Executive Office: Mallinckrodt plc Damastown Industrial Estate Mulhuddart, Dublin 15 Ireland U.S. Headquarters: 675 McDonnell Blvd. St. Louis, MO 63042 USA Website: www.mallinckrodt.com Stock Ticker: MNK Corporate Blog: http://blog.mallinckrodt.com/ Careers Website: www.mallinckrodt.com/careers Investor Relations: http://www.mallinckrodt.com/investors

Virginia Commonwealth University School of Medicine is a medical school that provides education, healthcare services, and conducts research.

Dedicated to its motto, Ut Prosim (That I May Serve), Virginia Tech takes a hands-on, engaging approach to education, preparing scholars to be leaders in their fields and communities. As the commonwealth’s most comprehensive university and its leading research institution, Virginia Tech offers 215 undergraduate and graduate degree programs to 31,000 students and manages a research portfolio of $450 million. The university fulfills its land-grant mission of transforming knowledge to practice through technological leadership and by fueling economic growth and job creation locally, regionally, and across Virginia.